Trial
NCT01532362
Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer
UnknownTERMINATEDSAFETYConfidence: HIGH
Sponsor
Jonsson Comprehensive Cancer Center
Collaborators
—
Condition
Non Small Cell Lung Cancer
Intervention
Apricoxib
Why stopped
Drug sponsor stopped drug manufacture due to toxicity issues from other studies
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-09-22